Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
Cancer Immunology, Immunotherapy, 05/14/2012
Becker JC et al. – Survivin–specific T–cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin–derived peptides is a promising treatment strategy in melanoma.



